Pro Research: Wall Street takes on Amgen's diverse prospects

investing.com:

Explore Wall Street's expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon. Enhance your investment strategy with ProPicks, our newest product featuring strategies that have outperformed the S&P 500 by up to 700%. This Cyber Monday, enjoy up to 60% off, plus an extra 10% off a 2-year subscription with the code research23 , reserved for the first 500 quick subscribers. To ensure ongoing access to valuable content like this, step up your investment game with InvestingPro.

In the dynamic landscape of the biopharmaceutical industry, Amgen Inc (NASDAQ:AMGN). stands as a company that has continually attracted Wall Street's attention. With a portfolio that spans across oncology, cardiovascular disease, and more recently, obesity treatments, Amgen's strategic moves and clinical progress have been subject to varied analyst opinions.

Amgen, primarily known for its medical research and drug development, has been making headlines with its Horizon acquisition and advancements in its obesity treatment assets. The company's oncology portfolio, including drugs like Tarlatamab and AMG-193, remains a strong suit, with multiple assets showing clinical progress. Analysts have noted investor interest in Amgen's pipeline, particularly in Tarlatamab and AMG-193, as they explore efficacy in different therapy lines and combinations.

Despite the challenging macroeconomic environment, Amgen has shown resilience in its stock performance. The company has maintained a competitive position within its drug class, with bullish sentiments stemming from strategic acquisitions and promising developments in key therapeutic areas. However, the stock has received mixed ratings from